Skip to main content

Stay Connected!

Join the email list.

Subscribe to receive info on unpublished research, current clinical trials, & general RET news.

2023 Happy Lungs Project RET Research Update

Scientific research update: Drs. John Heymach, Alexandre Drilon, and Alexandre Reuben shared the latest progress on their projects aimed at investigating new therapies for RET-inhibitor resistant disease and developing new immunotherapies for RET cancer.

Learn more

RET positive lung cancer is caused by a rare mutation of the RET gene that causes cancer cells to grow out of control.

This “driver mutation” occurs in about 2% of non-small cell lung cancer patients and is more common among young never-smokers, often the mothers of school-age children.

In many cases, it isn’t diagnosed until after the cancer has spread to other organs throughout the body. The Happy Lungs Project is dedicated to curing this disease.

Help us improve the lives of tens-of-thousands of RET positive survivors and their families.

Learn about The Happy Lungs Project

MISSION

Learn more

RESEARCH

Current projects

Mom's Story

SURVIVOR STORIES

Learn more

DONATE

Get involved

Shop & Make a Difference

Thanks for a fabulous first year and for shopping to save lives!

We hope you enjoyed using your Happy Lungs Shopping Card at retailers and restaurants around Austin. In total, more than 1,000 cards were sold! Together, we raised more than $50,000 for lung cancer research.

Join us next year Oct 27 – Nov 5, 2023. Sign up now!

The latest news and updates

Filter

oncogene testing RET lung cancer

Looking Ahead: The Future of Diagnostic Testing for Patients

By: Anthony Sireci, M.D., senior vice president, clinical biomarkers and diagnostics development, Loxo@Lilly Over the…
January 7, 2024
ret cancer research 2023

2023 RET Cancer Research Update

2023 Happy Lungs Project RET research update On Friday December 8th, the Happy Lungs Project…
December 18, 2023
RET lung cancer study 2023

Exciting Preclinical Results About Vepafestinib

New published study with exciting preclinical results about the second generation RET inhibitor vepafestinib (TAS0953/HM06).  Vepafestinib showed selectivity…
October 10, 2023

Help find a cure for RET Positive Lung Cancer.

Everyone counts.

We are all in this together.

2021

Established in

5

Research Projects

1

Funding to Date

90

Members

Proudly partnering with these organizations

MD Anderson lung cancer center
Lungeveity
RET positive group
Moving Beyond Cancer Collaborative